Amedisys (AMED)
(Real Time Quote from BATS)
$96.65 USD
-0.15 (-0.16%)
Updated Nov 8, 2024 03:55 PM ET
After-Market: $96.71 +0.06 (0.06%) 4:10 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.65 USD
-0.15 (-0.16%)
Updated Nov 8, 2024 03:55 PM ET
After-Market: $96.71 +0.06 (0.06%) 4:10 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
5 Mid-Cap Stocks For Growth Investors to Buy Right Now
by Awantika Poddar
Investing in mid-cap companies is a safe bet, especially during economic downturns and stringent credit conditions.
5 Growth Stocks at New Highs with Room for More Upside
by Sweta Killa
We have highlighted five growth stocks that hit all-time highs in the current market rally and will likely to continue to move higher given their superior fundamentals.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.
Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
Haemonetics Strong on Plasma Unit Amid Blood Center Weakness
by Zacks Equity Research
Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.
Hologic Launches Fluent Fluid Management System, Widens Suite
by Zacks Equity Research
Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.
Amedisys (AMED) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amedisys, Inc. (AMED).
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.
Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.
Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark
by Zacks Equity Research
Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.
Integra (IART) Reports In-Line Q2 Earnings, Tapers View
by Zacks Equity Research
Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.
Align Technology (ALGN) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.
Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.
Zacks.com highlights: HollyFrontier, Amedisys, MGM Growth Properties, Louisiana-Pacific and Houlihan Lokey
by Zacks Equity Research
Zacks.com highlights: HollyFrontier, Amedisys, MGM Growth Properties, Louisiana-Pacific and Houlihan Lokey
Bet on These 5 Low Leverage Stocks for Safe Returns
by Zacks Equity Research
As we are off to a strong start in the Q2 earnings season, blindly pursuing high earnings yielding stocks might drain all your money before you know, if the stock bears a high debt-to-equity ratio.
Weekly Jobless Claims Plunge to 48-Year Low: 5 Top Picks
by Nalak Das
Job additions continued to be substantial in June, indicating that hiring remains robust even as the economy nears full employment.
4 Reasons to Add Anadarko Petroleum (APC) to Your Portfolio
by Zacks Equity Research
Anadarko Petroleum (APC) seems a lucrative choice, promising better returns for investors on the back of four factors.
The Zacks Analyst Blog Highlights: Korn/Ferry International, Avis Budget Group, Regal Beloit, Amedisys and Jacobs Engineering Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Korn/Ferry International, Avis Budget Group, Regal Beloit, Amedisys and Jacobs Engineering Group
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.
Profit From Strong Job Additions With These 5 Top-Ranked Picks
by Swarup Gupta
June's jobs report indicates that corporations are successfully filling up open positions even as the pool of skilled workers continues to shrink.